Published On: Apr 29, 2021
Last Updated On: May 29, 2021
Apr 29, 2021
Download PDF
BALLERUP, Denmark, and MADISON, NJ, APRIL 29, 2021 – LEO Pharma A/S, a global leader in medical dermatology, today announced that the U.S. Food and Drug Administration (FDA) as part of their review of the company’s Biologics License Application (BLA) for tralokinumab, an investigational therapy for adults with moderate-to-severe atopic dermatitis, has issued a Complete Response Letter requesting additional data relating to a device component of tralokinumab. FDA did not request any new data on the clinical efficacy or safety of the drug product formulation of tralokinumab.
“We are committed to bringing tralokinumab to the market to support the millions of U.S. adults who live with uncontrolled moderate-to-severe atopic dermatitis. The FDA has not raised any questions to the clinical efficacy or safety of tralokinumab, but only requested additional data relating to a device component of the combination product. We will now work closely with the FDA to address their request and bring tralokinumab to the U.S. patients as quickly as possible.” said Jörg Möller, Executive Vice President, Global Research and Development at LEO Pharma.
The BLA submission was based on efficacy and safety results from the ECZTRA 1, 2 and ECZTRA 3 pivotal Phase 3 trials, which included more than 1,900 adult patients with moderate-to-severe atopic dermatitis. Safety data was evaluated from a pool of five randomized, double-blind, placebo-controlled trials, including ECZTRA 1, 2 and ECZTRA 3, a dose-finding trial, and a vaccine response trial.1
LEO Pharma received a positive opinion for tralokinumab from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on April 22, 2021.
About atopic dermatitis
Atopic dermatitis is a chronic, inflammatory, skin disease characterized by intense itch and eczematous lesions.1 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.2 Type 2 cytokines, including IL-13, play a central role in the key aspects of atopic dermatitis pathophysiology.3
About tralokinumab
Tralokinumab is the first fully human, monoclonal antibody developed to specifically neutralize the IL-13 cytokine, which plays a key role in driving the underlying atopic dermatitis signs and symptoms.3,4 Tralokinumab specifically binds to the IL-13 cytokine with high affinity, thereby inhibiting interaction with the IL-13 receptor α1-subunit of the type 2 receptor.3,4
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in 130 countries. In 2020, the company generated net sales of DKK 10,133 million. For more information, please visit www.LEO-Pharma.com.
Contacts
Linda Mayer
Global Product Communications
+1 973 908 7924
limay@leo-pharma.com
Henrik Kyndlev
Global External Communications
+45 3140 6180
hdtdk@leo-pharma.com
References
March 2021 MAT-42
LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) for delgocitinib cream 20 mg/g (2%) for the treatment of adults with moderate to severe Chronic Hand Eczema (CHE), who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
Eli Lilly and Company announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
Arcutis Biotherapeutics, Inc., today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ZORYVE (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.
Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
Evidence-based articles, expert-sourced lifestyle tips and stories from your community.